Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA-SFC in Type 2 Diabetes
NCT02481141Completed
- Sponsor
- SBI Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
01
Overview
Randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing 5-ALA-SFC with Placebo (2 arms). Primary endpoints: Subjects With Adverse Events as a Measure of Safety and Tolerability at 12 weeks and Change From Baseline in Fasting Blood Glucose at 12 weeks. Started Jul 2014; status: completed.
02
Drugs
5-aminolevulinic acid hydrochloride + sodium ferrous citrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02481141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481141.